New eye drug OLN324 tested for wet AMD and diabetic swelling
Disease control
Completed
This early-phase trial tested an investigational eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves in the body, with a preliminary look at whet…
Phase: PHASE1 • Sponsor: Ollin Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC